Diabetes and outcomes following personalized antiplatelet therapy in coronary artery disease patients who underwent PCI.
Ying-Ying ZhengTing-Ting WuYi YangXian-Geng HouYou ChenXiang MaYi-Tong MaJin-Ying ZhangYing-Ying ZhengPublished in: The Journal of clinical endocrinology and metabolism (2021)
The present study suggests that personalized antiplatelet therapy according to PFT can reduce ischemic events but not increase bleedings in stable CAD patients with or without diabetes who underwent PCI.
Keyphrases
- antiplatelet therapy
- percutaneous coronary intervention
- coronary artery disease
- acute coronary syndrome
- st segment elevation myocardial infarction
- acute myocardial infarction
- st elevation myocardial infarction
- type diabetes
- end stage renal disease
- coronary artery bypass grafting
- cardiovascular disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- cardiovascular events
- glycemic control
- peritoneal dialysis
- atrial fibrillation
- coronary artery bypass
- metabolic syndrome
- insulin resistance
- ischemia reperfusion injury
- aortic valve
- patient reported outcomes
- adipose tissue